Respirerx Pharma Stock Price, News & Analysis

RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) has announced the publication of a manuscript detailing the pharmacology of its compound KRM-II-81, marking a significant advancement in developing GABAkines for neurological and psychiatric disorders. The paper describes KRM-II-81's efficacy against pharmacoresistant epilepsy and neuropathic pain, showcasing its low sedation effects and lack of tolerance development. The company's leadership sees potential in KRM-II-81 as a breakthrough treatment, moving towards IND enabling studies to address significant unmet medical needs.

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announces participation in two upcoming investor conferences. CFO Jeff Margolis will present live at the Life Sciences Virtual Investor Conference on December 16, 2021, discussing the company’s vision and programs. Concurrently, President and CEO Tim Jones will present a pre-recorded video at the Biotech Showcase from January 17-19, 2022. These platforms offer insights into RespireRx's innovative treatments for psychiatric and neurological disorders, including obstructive sleep apnea and ADHD.

RespireRx Pharmaceuticals (OTCQB: RSPI) has published a pivotal review article on GABAkines, focusing on the development of positive allosteric modulators of GABA_A receptors. This article highlights the potential of KRM-II-81, a GABAkine in development, to treat epilepsy and pain with reduced side effects compared to traditional benzodiazepines. KRM-II-81 shows promise in preclinical studies, demonstrating high anti-convulsant and analgesic activities without the risks of tolerance or dependence. The findings strongly support advancements in treatment options for neurological disorders.

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the publication of research on KRM-II-81, a novel analgesic, in the book The Neurobiology, Physiology, and Psychology of Pain. This compound selectively potentiates GABA_A receptors, showing significant analgesic efficacy without common opioid side effects. KRM-II-81 demonstrated comparable or superior analgesic effects in animal models compared to traditional analgesics, while avoiding tolerance, dependence, and respiratory depression. The company is optimistic about KRM-II-81's potential to address pain management amidst the opioid crisis.

RespireRx Pharmaceuticals (OTCQB: RSPI) announced two significant peer-reviewed studies led by Dr. David Fuller, demonstrating the potential of AMPAkines CX1739 and CX717 to enhance motor nerve activity and muscle function in spinal cord injury models. The first study highlights CX717's effectiveness in increasing motor output in rats, while the second showcases improvements in diaphragm activity and overall motor functioning in awake rats post-spinal injury. These findings bolster hopes for AMPAkines as therapeutic alternatives for spinal cord injury recovery, paving the path toward human clinical trials.

On November 22, 2021, RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) announced the availability of a podcast featuring CEO Timothy Jones. Recorded on October 21, 2021, and released by OTC Markets on November 17, 2021, the podcast discusses the company's business units, including pharmaceutical cannabinoids and neuromodulators, along with targeted therapeutic indications such as Obstructive Sleep Apnea and ADHD. Notably, potential offerings pursuant to Regulation A were not discussed. The company emphasizes its commitment to addressing unmet medical needs through innovative therapies.

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) has released a video interview featuring CFO Jeff Margolis, providing insights into the company's structure, programs, and market opportunities. The interview is accessible to the public on November 4, 2021, via ProActive Investors and RespireRx's website. Margolis discussed the upcoming Regulation A offering and the preliminary offering amount of 250 million shares priced between $0.02 and $0.03 per share, aiming for a maximum raise of $7.5 million. This offering is pending SEC qualification.

RespireRx Pharmaceuticals (OTCQB: RSPI) will participate in the Access China Biotech 2021 Digital conference from June 9-14, 2021. This event facilitates connections between Western pharmaceutical and biotech leaders and Chinese companies. RespireRx focuses on developing treatments for neurological disorders, specifically targeting conditions like obstructive sleep apnea and ADHD. The company aims to advance its innovative drug candidates based on cannabinoids and neuromodulators. Their corporate presentation is available online for stakeholders.

RespireRx Pharmaceuticals (OTCQB: RSPI) announces a significant advancement in spinal cord injury treatment. At the Annual Experimental Biology Conference, researchers presented findings demonstrating that low doses of AMPAkines CX717 and CX1739 effectively increase diaphragm activity and tidal volume in non-anesthetized rats post-cervical spinal cord injury. The ongoing collaboration with the University of Florida is focused on developing a Phase 2 clinical trial aimed at restoring motor functions in patients with spinal cord injury. This research highlights the potential of AMPAkines as a groundbreaking treatment option.